Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
SALT LAKE CITY, Nov. 06, 2024 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial…
MaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes
Completion of enrollment in the European Phase 3 clinical trial ARES designed to evaluate efficacy and safety of MaaT013 in the treatment of acute Graft-versus-Host Disease; topline results expected in…
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology…
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Cue Biopharma, Inc. BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and…
MindMed Reports Second Quarter 2024 Financial Results and Business Updates
–Completed End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA); on track to initiate Phase 3 clinical program for MM120 orally disintegrating tablet (ODT) in Generalized Anxiety…